Company Overview
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $8.98M (+28.1% YoY); net profit $-48.79M.
- Trailing 12 Months Year-on-year growth — revenue -0.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.67% |
| 1 Year: | -0.40% |
Stock Price Performance
| 1 Year: | -66.80% |
| 6 Months: | -49.69% |
| 3 Months: | +1.23% |
| 1 Month: | +12.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)48.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 66.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NSPR InspireMD, Inc. PHARMA | 0.83 | -1.36 | $38.88M | 0.00% | -84.53% | - | 6.67% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 640.00K | 718.00K | 1.01M | 1.00M | 769.00K | 415.00K | 1.35M | 939.00K | 1.03M | 313.00K | 980.00K | 1.01M | 1.04M | 1.07M | 1.18M | 1.53M | 1.43M | 1.24M | 1.65M | 1.56M | 1.51M | 1.74M | 1.81M | - | 1.53M | 1.78M | 2.52M | 3.15M | 3.40M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.24M | 1.47M | 1.66M | 1.97M | 2.71M |
| Gross Profit | 802.00K | 857.00K | -391.00K | -76.00K | -37.00K | -212.00K | 89.00K | 66.00K | 62.00K | 30.00K | 74.00K | 147.00K | 153.00K | 293.00K | 277.00K | 198.00K | -73.00K | 442.00K | 128.00K | 295.00K | -120.00K | 298.00K | 106.00K | 262.00K | 92.00K | 122.00K | 431.00K | 366.00K | 373.00K | 491.00K | 438.00K | 292.00K | 331.00K | 414.00K | - | 292.00K | 313.00K | 864.00K | 1.18M | 687.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.75M | 13.33M | 13.91M | 13.26M | 14.66M |
| Operating Income | -3.88M | -5.54M | -7.24M | -6.48M | -4.89M | -3.57M | -3.41M | -2.03M | -1.77M | -1.76M | -2.40M | -2.29M | -2.08M | -1.95M | -1.47M | -1.98M | -3.13M | -2.18M | -2.00M | -2.02M | -2.45M | -2.19M | -3.31M | -3.44M | -4.03M | -4.49M | -4.68M | -4.61M | -4.38M | -5.32M | -5.64M | -7.41M | -8.26M | -8.46M | - | -11.46M | -13.02M | -13.05M | -12.08M | -13.98M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.36M | -12.91M | -12.92M | -11.94M | -13.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.17M | -13.15M | -12.71M | -11.70M | -13.69M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.94M | -5.97M | -7.56M | -6.78M | -5.21M | -3.88M | -3.64M | -2.25M | -1.95M | -2.00M | -2.56M | -2.29M | -2.09M | -2.39M | -627.00K | -2.01M | -3.21M | -2.21M | -2.07M | -1.98M | -2.48M | -2.23M | -3.24M | -3.51M | -4.07M | -4.48M | -4.64M | -4.53M | -4.26M | -5.08M | -5.18M | -7.03M | -7.91M | -7.89M | - | -11.17M | -13.15M | -12.71M | -11.76M | -13.69M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.59 | -0.58 | -0.53 | -0.24 | -0.15 | -0.21 | -0.22 | -0.16 | - | -0.22 | -0.26 | -0.17 | -0.14 | -0.16 |
| R&D Expense | 1.54M | 2.58M | 2.45M | 2.46M | 1.35M | 747.00K | 781.00K | 379.00K | 278.00K | 289.00K | 350.00K | 403.00K | 288.00K | 252.00K | 230.00K | 416.00K | 1.12M | 865.00K | 442.00K | 523.00K | 444.00K | 546.00K | 839.00K | 1.29M | 1.50M | 1.68M | 2.06M | 2.06M | 1.84M | 1.99M | 2.11M | 2.62M | 3.40M | 3.92M | - | 4.06M | 3.83M | 3.63M | - | 4.76M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Jun 2012 | Jun 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.41M | 4.95M | 6.00M | 5.35M | 4.87M | 2.82M | 2.31M | 1.89M | 2.76M | 3.60M | 3.72M | 2.48M | - | 5.17M | 6.21M | 7.01M | 8.98M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.05M | 4.40M | 5.50M | 6.33M |
| Gross Profit | 1.12M | 2.25M | 2.99M | 2.50M | 2.59M | 784.00K | -296.00K | 102.00K | 585.00K | 995.00K | 756.00K | 83.00K | - | 1.12M | 1.81M | 1.51M | 2.65M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.83M | 22.95M | 35.01M | 52.26M |
| Operating Income | -2.72M | -3.22M | -13.73M | -17.55M | -15.07M | -23.70M | -14.48M | -7.65M | -8.23M | -7.61M | -9.82M | -10.38M | - | -18.71M | -21.14M | -33.50M | -49.61M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.52M | -20.91M | -33.22M | -49.14M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 157.00K | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.46M | -19.85M | -31.95M | -48.72M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.00K | 65.00K | 59.00K | 63.00K |
| Net Income | -2.72M | -3.42M | -14.66M | -17.60M | -29.26M | -25.09M | -15.59M | -8.46M | -8.44M | -7.24M | -10.04M | -10.54M | - | -18.49M | -19.92M | -32.01M | -48.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.35 | -0.82 | -0.76 | -0.76 |
| R&D Expense | 1.33M | 1.34M | 2.47M | 3.99M | 4.16M | 8.74M | 3.64M | 1.29M | 1.28M | 1.53M | 2.95M | 2.23M | 5.16M | 7.81M | 7.98M | 13.63M | 15.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Jun 2011 | Dec 2011 | Jun 2012 | Jun 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 4.36M | - | 10.46M | 16.01M | 20.75M | 23.97M | 11.46M | 5.69M | 9.41M | 6.11M | 12.29M | 9.88M | 17.78M | 39.71M | 24.65M | 47.64M | 46.81M | 69.40M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.33M | 44.16M | 40.52M | 61.47M |
| Cash & Equivalents | 1.57M | 376.00K | 636.00K | 8.07M | 5.09M | 10.28M | 14.82M | 17.54M | 6.30M | 3.26M | 7.52M | 3.71M | 9.38M | 5.51M | 12.64M | 12.00M | 4.63M | 9.64M | 18.92M | 8.94M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.62M | 2.11M | 2.57M | 3.40M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03M | 1.80M | 1.57M | 2.17M |
| Total Liabilities | - | - | 5.27M | - | 3.71M | 10.63M | 4.64M | 15.33M | 14.25M | 8.64M | 5.37M | 3.11M | 3.52M | 4.50M | 5.61M | 6.18M | 7.26M | 8.14M | 10.72M | 14.20M |
| Current Liabilities | - | - | 3.94M | - | 3.44M | 3.55M | 4.04M | 6.12M | 8.47M | 6.83M | 4.78M | 2.48M | 2.92M | 3.12M | 3.71M | 4.35M | 5.07M | 6.02M | 7.68M | 10.71M |
| Long Term Debt | - | - | 75.00K | - | - | - | - | - | 5.09M | 1.10M | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.61M | 1.59M | 2.34M | 3.29M |
| Total Equity | 134.00K | -1.34M | -914.00K | 7.16M | 6.75M | 5.39M | 16.10M | 8.64M | -2.79M | -2.95M | 4.04M | 2.73M | 8.76M | 5.38M | 12.16M | 33.53M | 17.39M | 39.50M | 36.09M | 55.20M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.33M | 21.84M | 26.61M | 43.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Jun 2012 | Jun 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.54M | -2.71M | -6.00M | -8.58M | -10.30M | - | - | - | -8.13M | -7.61M | -9.81M | -9.08M | - | -15.54M | -16.38M | -21.87M | -35.10M |
| Investing Cash Flow | -346.00K | -46.00K | 13.00K | -43.00K | -376.00K | - | - | - | -318.00K | -44.00K | -387.00K | -187.00K | - | 8.44M | -16.09M | 12.64M | -30.56M |
| Financing Cash Flow | 655.00K | 3.04M | 10.67M | 11.07M | 15.12M | - | - | - | 4.63M | 13.37M | 6.33M | 16.39M | - | -140.00K | 37.53M | 18.45M | 55.57M |
| Capital Expenditure | -34.00K | -81.00K | -139.00K | -290.00K | -202.00K | -133.00K | -16.00K | -49.00K | -258.00K | -67.00K | -284.00K | -88.00K | - | -473.00K | -381.00K | -1.40M | -1.66M |
| Free Cash Flow | -1.58M | -2.79M | -6.14M | -8.87M | -10.50M | - | - | - | -8.39M | -7.67M | -10.09M | -9.17M | - | -16.02M | -16.76M | -23.27M | -36.77M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.24M | 5.07M | 9.22M | -10.09M |
| Share Buybacks | - | - | - | 21.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Jun 2012 | Jun 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 32.8% | 45.5% | 49.9% | 46.7% | 53.2% | 27.8% | -12.8% | 5.4% | 21.2% | 27.6% | 20.3% | 3.3% | - | 21.6% | 29.1% | 21.5% | 29.5% |
| Operating Margin % | -79.7% | -65.0% | -228.7% | -328.0% | -309.3% | -841.0% | -627.1% | -403.8% | -298.2% | -211.4% | -263.8% | -417.7% | - | -361.9% | -340.7% | -478.0% | -552.6% |
| Net Margin % | -79.9% | -69.1% | -244.3% | -329.0% | -600.4% | -890.5% | -674.7% | -446.7% | -305.6% | -201.1% | -269.8% | -424.3% | - | -357.6% | -321.0% | -456.6% | -543.3% |
| ROE % | 203.4% | 374.2% | -217.1% | -326.7% | -181.7% | 900.4% | 529.0% | -209.2% | -309.4% | -82.6% | -186.5% | -86.7% | - | -106.3% | -50.4% | -88.7% | -88.4% |
| ROCE % | - | -783.2% | -195.5% | -140.8% | -90.2% | -793.6% | 1,269.5% | -165.1% | -227.1% | -81.2% | -145.1% | -73.8% | - | -95.6% | -50.8% | -85.6% | -84.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 8.40% | 3.91M | $3.00M |
| 2 | Aberdeen Group plc | 7.96% | 3.70M | $2.84M |
| 3 | Nantahala Capital Management, LLC | 7.26% | 3.38M | $2.59M |
| 4 | Orbimed Advisors LLC. | 6.74% | 3.13M | $2.40M |
| 5 | Parkman Healthcare Partners LLC | 5.20% | 2.42M | $1.85M |
| 6 | Marshall Wace LLP | 4.00% | 1.86M | $1.43M |
| 7 | Soleus Capital Management, L.P. | 2.25% | 1.05M | $802.48K |
| 8 | Pura Vida Investments, Llc | 0.97% | 450.52K | $345.73K |
| 9 | Ingalls & Snyder LLC | 0.79% | 368.80K | $283.02K |
| 10 | Affiance Financial, LLC | 0.54% | 250.37K | $192.13K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NSPR
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of In…
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C.…
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know
InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
InspireMD Inc (NSPR) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges While ...
Despite flat revenue and a widened net loss from recall-related charges, InspireMD's international growth and promising trial results for its CGuard platforms signal a strategic path forward.
InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17th, at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for t…
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
NSPR — Frequently Asked Questions
What is the current share price of InspireMD, Inc. (NSPR)?
As of 2026-09-19 21:16 PDT, InspireMD, Inc. (NSPR) trades at $0.83 on NasdaqCM. Its 52-week range is $0.65 to $2.50.
What is the market capitalisation of NSPR?
InspireMD, Inc. (NSPR) has a market capitalisation of $38.88M on NasdaqCM.
What is the P/E ratio of NSPR?
NSPR trades at a trailing price-to-earnings (P/E) ratio of -1.36. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.14.
Is NSPR a good stock to buy?
This page provides a data-driven analysis of InspireMD, Inc. (NSPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.